Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-Class Bispecifics for I&I Diseases

Velocity timeline

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

Coverage (5)

• JATT II Acquisition to Merge With Talawar Tx; JATT to Become Subsidiary in SPAC Deal TradingView · 8h ago
• Biotech SPAC deal gets it to Nasdaq; AstraZeneca Phase 3 win in children's bone disease Endpoints News · 8h ago
• Talawar bets bispecific approach can shake up eczema market statnews.com · 8h ago
• 'There's room for multiple winners': Talawar heads to Nasdaq via SPAC deal to bankroll eczema asset Fierce Biotech · 8h ago
• Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-Class Bispecifics for I&I Diseases PR Newswire · 8h ago broke it first

Related trends